Cardiologists Push Back On Proposed Transcatheter Valve Credentialing Proposals

Clinicians say some of the procedural experience requirements proposed by CMS and societies as prerequisites for conducting transcatheter aortic valve replacements might overly limit access to the technology. ACC has made some revisions to its proposal in response.

The minimum experience that interventional cardiologists and surgeons would need to have to participate in a Medicare-covered transcatheter aortic valve replacement program under a proposal issued last month has many physicians worried that access to the promising new procedure could be overly restricted.

But the credentialing requirements in CMS’ national coverage proposal, released Feb. 2, are based on guidance from the main professional medical societies representing practitioners who will be performing the procedure, recently available in the U.S. via the November 2011 FDA-approval of Edwards Lifesciences’ Sapien valve. And those groups, the American College of Cardiology, the Society of Thoracic Surgeons, the American Association of Thoracic Surgery and the Society for Cardiovascular Angiography and Interventions, issued a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By 

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By 

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.